Back to search results

Palliative Radiation for Bone Metastases

This study is testing a new way to deliver radiation therapy called "simulation-free, single-fraction palliative radiation therapy" for people with bone metastases (cancer that has spread to the bones). The goal is to see if this treatment can be given in a single visit, making it simpler for patients. For this study, success means that the treatment is given exactly as planned in the protocol. You might be able to join if you are 18 or older, have any cancer with one or two painful bone metastases, and your doctor thinks single-fraction radiation therapy is right for you. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 40 participants. The study is testing a specific radiation therapy approach.
What's involved
Participants will receive a single dose of radiation therapy (8 Gy) in one in-person visit.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 1 day after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07202273

Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases

Recruiting
NAAges 18+InterventionalTreatment
University of Utah
~40 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:simulation-free, single-fraction palliative radiation therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess the rate at which the intervention is delivered with fidelity to protocol.
Measured over 1 day

Conditions

Bone Metastases

Explore related trials

Metastatic Malignant Neoplasm in the Bone

NCT07202273

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utahstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Rachel Kingford
[email protected]
8015850115
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant aged ≥ 18 years.
Diagnosis of any cancer with one to two sites of painful and treatable metastatic bone lesions.
Bone metastases are causing pain or instability in the opinion of the treating investigator.
Amenable to single fraction radiation therapy per the discretion of the treating physician.
CT collected within 60 days of registration with adequate visualization of target site as determined by the treating investigator.
ECOG Performance Status ≤ 2.
Participants must adhere to the following sex and contraceptive/barrier requirements:
If participant is of childbearing potential, they must have a negative pregnancy test ≤ 14 days before the planned date of radiation therapy. This may be completed on the day of radiation if results from the pregnancy test are available for review before treatment.
For participants of non-child bearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:
\< 50 years of age:
Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and
Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
≥ 50 years of age:
Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or
Had radiation-induced menopause with last menses \>1 year ago; or
Had chemotherapy-induced menopause with last menses \>1 year ago
Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception.
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion

Evidence of spinal cord compression caused by the bone metastases to be treated.
Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.
Participants taking prohibited medications as described in Section 6.7.1.

What this trial measures

  • To assess the rate at which the intervention is delivered with fidelity to protocol.1 day

    To provide proof-of-concept that patients can be treated with simulation-free, single-fraction palliative radiation therapy with only a single in-person visit to Huntsman Cancer Hospital (HCH). This will be defined as receiving simulation-free, single-fraction radiation therapy with documented real-time approval by the radiation oncologist, medical physicist, and radiation therapist that the treatment adequately covers the target without unreasonable or unsafe differences.